 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...79808182838485868788899091» |
- levofloxacin / Generic mfg.
Enrollment open: BISER-2: Sputum Microbiota and the Association With Clinical Parameters in Steady-state, Acute Exacerbation and Convalescence of Bronchiectasis (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=120, Recruiting, Sponsor: Guangzhou Institute of Respiratory Disease
Not yet recruiting --> Recruiting
- Sutent (sunitinib) / Pfizer
Trial completion: RISQ-PATH: Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=178, Completed, Sponsor: Katholieke Universiteit Leuven
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | levofloxacin / Generic mfg., prulifloxacin / Generic mfg.
Trial completion: A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control (clinicaltrials.gov) - Jul 16, 2015
P3, N=216, Completed, Sponsor: Lee's Pharmaceutical Limited
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Zemdri (plazomicin) / Ionis, Achaogen
New P3 trial: EPIC: A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) (clinicaltrials.gov) - Jul 1, 2015
P3, N=530, Not yet recruiting, Sponsor: Achaogen, Inc.
- | Zabolante (zabofloxacin) / Dong Wha
Trial completion, Trial primary completion date: Bacteriocide: Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin (clinicaltrials.gov) - Jun 29, 2015
P1, N=18, Completed, Sponsor: Dong Wha Pharmaceutical Co. Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Aug 2014
- levofloxacin / Generic mfg.
Trial primary completion date: Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations (clinicaltrials.gov) - Jun 11, 2015
P3, N=70, Recruiting, Sponsor: University of Rochester
Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Aug 2014 Trial primary completion date: Jan 2015 --> Jan 2020
- | New P4 trial: Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients (clinicaltrials.gov) - Jun 9, 2015
P4, N=200, Enrolling by invitation, Sponsor: Chung-Tai Wu
- || Sirturo (bedaquiline) / J&J, Pharmstandard
New P2/3 trial: An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis (clinicaltrials.gov) - May 27, 2015
P2/3, N=300, Not yet recruiting, Sponsor: University of Cape Town
- |||||||||| levofloxacin / Generic mfg., prulifloxacin / Generic mfg.
New P3 trial: A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control (clinicaltrials.gov) - May 12, 2015
P3, N=216, Active, not recruiting, Sponsor: Lee's Pharmaceutical Limited
- levofloxacin / Generic mfg., cloxacillin / Generic mfg.
Trial completion, Enrollment change: Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus. (clinicaltrials.gov) - May 1, 2015
P3, N=1, Completed, Sponsor: Fundaci
Trial primary completion date: Jan 2015 --> Jan 2020 Recruiting --> Completed | N=154 --> 1
- Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Apr 28, 2015
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=154 --> 1 Trial primary completion date: May 2016 --> Jun 2018
- || nitazoxanide / Generic mfg.
New P3 trial: Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori (clinicaltrials.gov) - Apr 21, 2015
P3, N=120, Recruiting, Sponsor: Sherief Abd-Elsalam
- | levofloxacin / Generic mfg., ceftaroline fosamil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (clinicaltrials.gov) - Apr 8, 2015
P4, N=12, Completed, Sponsor: Gary E. Stein, Pharm.D.
Trial primary completion date: May 2016 --> Jun 2018 Recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Dec 2014 --> May 2014
- || Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard
New P3 trial: STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (clinicaltrials.gov) - Apr 6, 2015
P3, N=1155, Not yet recruiting, Sponsor: IUATLD, Inc
- Sirturo (bedaquiline) / J&J, Pharmstandard
Enrollment open: An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (clinicaltrials.gov) - Mar 21, 2015
P2, N=5, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Completed | N=16 --> 12 | Trial primary completion date: Dec 2014 --> May 2014 Not yet recruiting --> Recruiting
- Trial primary completion date: BISER: Bacteriology and Inflammation in Bronchiectasis (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=80, Recruiting, Sponsor: Guangzhou Institute of Respiratory Disease
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2013 --> Dec 2017
- levofloxacin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Pharmacokinetics of Levofloxacin in Intensive Care Unit (clinicaltrials.gov) - Mar 7, 2015
P4, N=52, Completed, Sponsor: University Hospital, Toulouse
Trial primary completion date: Sep 2013 --> Dec 2017 Recruiting --> Completed | N=65 --> 52 | Trial primary completion date: Dec 2014 --> Sep 2014
- Sirturo (bedaquiline) / J&J, Pharmstandard
New P2 trial: An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (clinicaltrials.gov) - Feb 19, 2015
P2, N=5, Not yet recruiting, Sponsor: Janssen Pharmaceutical K.K.
- Zabolante (zabofloxacin) / Dong Wha
Enrollment closed, Trial primary completion date: Bacteriocide: Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin (clinicaltrials.gov) - Feb 12, 2015
P1, N=18, Active, not recruiting, Sponsor: Dong Wha Pharmaceutical Co. Ltd.
Recruiting --> Completed | N=65 --> 52 | Trial primary completion date: Dec 2014 --> Sep 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Apr 2015
- Sutent (sunitinib) / Pfizer
Enrollment closed: RISQ-PATH: Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital (clinicaltrials.gov) - Feb 11, 2015
P=N/A, N=175, Active, not recruiting, Sponsor: Katholieke Universiteit Leuven
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- levofloxacin / Generic mfg.
Enrollment open, Trial initiation date, Combination therapy: Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (clinicaltrials.gov) - Feb 5, 2015
P2, N=100, Recruiting, Sponsor: Boston University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> Jan 2015
- ||||| Taigexyn (nemonoxacin) / TaiGen
Trial initiation date: A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP (clinicaltrials.gov) - Feb 3, 2015
P3, N=540, Recruiting, Sponsor: TaiGen Biotechnology Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> Jan 2015 Initiation date: Feb 2014 --> Jun 2014
- ||||| ilaprazole / Generic mfg., levofloxacin / Generic mfg.
New P4 trial: Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori (clinicaltrials.gov) - Feb 2, 2015
P4, N=80, Recruiting, Sponsor: Il-Yang Pharm. Co., Ltd.
- levofloxacin / Generic mfg.
Clinical: BISER-2: Sputum Microbiota and the Association With Clinical Parameters in Steady-state, Acute Exacerbation and Convalescence of Bronchiectasis (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=120, Not yet recruiting, Sponsor: Guangzhou Institute of Respiratory Disease
- levofloxacin / Generic mfg.
Trial primary completion date: Pharmacokinetics of Levofloxacin in Intensive Care Unit (clinicaltrials.gov) - Dec 7, 2014
P4, N=65, Recruiting, Sponsor: University Hospital, Toulouse
Initiation date: Feb 2014 --> Jun 2014 Trial primary completion date: Mar 2014 --> Dec 2014
- Invanz (ertapenem) / Merck (MSD)
Enrollment closed: APPAC: Appendicectomy Versus Antibiotics in the Treatment of Acute Uncomplicated Appendicitis (clinicaltrials.gov) - Dec 7, 2014
P=N/A, N=530, Active, not recruiting, Sponsor: Turku University Hospital
Trial primary completion date: Mar 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- levofloxacin / Generic mfg.
Trial primary completion date: Pharmacokinetic Evaluation of Fluoroquinolone Antibiotics Administered Intravenously in Intensive Care Patients With Normal Renal Function and With Renal Hyperfiltration (clinicaltrials.gov) - Dec 6, 2014
P3, N=40, Recruiting, Sponsor: University Ghent
Recruiting --> Active, not recruiting Trial primary completion date: May 2013 --> May 2015
- levofloxacin / Generic mfg., cloxacillin / Generic mfg.
Trial primary completion date: Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus. (clinicaltrials.gov) - Dec 5, 2014
P3, N=154, Recruiting, Sponsor: Fundaci
Trial primary completion date: May 2013 --> May 2015 Trial primary completion date: Jun 2014 --> Jan 2015
- ceftriaxone / Generic mfg.
Enrollment change, Trial termination: EVOTAR: Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients. (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=77, Terminated, Sponsor: Assistance Publique - H
Trial primary completion date: Jun 2014 --> Jan 2015 N=300 --> 77 | Active, not recruiting --> Terminated; lack of recruitement
- |||| levofloxacin / Generic mfg.
Trial completion: Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study (clinicaltrials.gov) - Oct 17, 2014
P4, N=154, Completed, Sponsor: Ottawa Hospital Research Institute
N=300 --> 77 | Active, not recruiting --> Terminated; lack of recruitement Active, not recruiting --> Completed
- loperamide / Generic mfg., azithromycin / Generic mfg.
Trial primary completion date: Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=510, Recruiting, Sponsor: Uniformed Services University of the Health Sciences
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Apr 2015
- ceftriaxone / Generic mfg.
Enrollment closed, Trial primary completion date: EVOTAR: Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients. (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=300, Active, not recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Sep 2014 --> Apr 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2014
- | Vabomere (meropenem/vaborbactam) / Melinta Therap
Enrollment open: Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP (clinicaltrials.gov) - Sep 4, 2014
P3, N=850, Recruiting, Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2014 Not yet recruiting --> Recruiting
- Enrollment open: Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis (clinicaltrials.gov) - Aug 19, 2014
P2, N=128, Recruiting, Sponsor: Vanderbilt University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Zabolante (zabofloxacin) / Dong Wha
New P1 trial: Bacteriocide: Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin (clinicaltrials.gov) - Aug 8, 2014
P1, N=18, Recruiting, Sponsor: Dong Wha Pharmaceutical Co. Ltd.
- ||||| levofloxacin / Generic mfg.
Enrollment change: Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Aug 7, 2014
P3, N=740, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=592 --> 740
- levofloxacin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: FLISH-ILT: "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". (clinicaltrials.gov) - Aug 6, 2014
P3, N=68, Terminated, Sponsor: Fundaci
N=592 --> 740 N=870 --> 68 | Recruiting --> Terminated | Trial primary completion date: Nov 2014 --> Feb 2014; Recruitment rythm not sufficent to reach the simple size needed.
- levofloxacin / Generic mfg.
Enrollment change: Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy (clinicaltrials.gov) - Aug 5, 2014
P4, N=600, Recruiting, Sponsor: National Taiwan University Hospital
N=870 --> 68 | Recruiting --> Terminated | Trial primary completion date: Nov 2014 --> Feb 2014; Recruitment rythm not sufficent to reach the simple size needed. N=440 --> 600
- |||||||||| Taigexyn (nemonoxacin) / TaiGen
New P3 trial: A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP (clinicaltrials.gov) - Aug 1, 2014
P3, N=540, Recruiting, Sponsor: TaiGen Biotechnology Co., Ltd.
- levofloxacin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg., duloxetine / Generic mfg.
Trial primary completion date: Rechallenge, Potential Drug Induced Liver Injury (Kaiser) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
N=440 --> 600 Trial primary completion date: Feb 2014 --> Apr 2013
- Decadron (dexamethasone) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial termination: Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach (clinicaltrials.gov) - Jul 8, 2014
P2, N=17, Terminated, Sponsor: New Mexico Cancer Care Alliance
Trial primary completion date: Feb 2014 --> Apr 2013 Active, not recruiting --> Terminated; Low rate of accrual
- Decadron (dexamethasone) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change, Trial termination: Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach (clinicaltrials.gov) - Jul 8, 2014
P2, N=17, Terminated, Sponsor: New Mexico Cancer Care Alliance
Active, not recruiting --> Terminated; Low rate of accrual N=35 --> 17 | Active, not recruiting --> Terminated; Low rate of accrual
- levofloxacin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg., duloxetine / Generic mfg.
Trial completion, Trial primary completion date: Rechallenge, Potential Drug Induced Liver Injury (Kaiser) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
N=35 --> 17 | Active, not recruiting --> Terminated; Low rate of accrual Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Apr 2013
- levofloxacin / Generic mfg.
Clinical: Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=20, Completed, Sponsor: University Medical Centre Groningen
- || Vabomere (meropenem/vaborbactam) / Melinta Therap
New P3 trial: Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP (clinicaltrials.gov) - Jun 19, 2014
P3, N=850, Not yet recruiting, Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- Sutent (sunitinib) / Pfizer
Trial primary completion date: RISQ-PATH: Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=175, Recruiting, Sponsor: Katholieke Universiteit Leuven
Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Apr 2013 Trial primary completion date: Dec 2014 --> Mar 2015
- Taksta (fusidic acid) / Idera
Trial primary completion date: Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection (clinicaltrials.gov) - Jun 8, 2014
P2, N=14, Terminated, Sponsor: Cempra Pharmaceuticals
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Mar 2014 --> Jul 2014
- Taksta (fusidic acid) / Idera
Trial termination: Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection (clinicaltrials.gov) - Jun 8, 2014
P2, N=14, Terminated, Sponsor: Cempra Pharmaceuticals
Recruiting --> Terminated; This study has been terminated; alternative study designs are being considered. Fusidic acid remains available under an Expanded Access Protocol.
- Taksta (fusidic acid) / Idera
Enrollment change: Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection (clinicaltrials.gov) - Jun 8, 2014
P2, N=14, Terminated, Sponsor: Cempra Pharmaceuticals
Fusidic acid remains available under an Expanded Access Protocol. N=50 --> 14
- |||||||||| levofloxacin / Generic mfg., prulifloxacin / Generic mfg.
New P3 trial: A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control (clinicaltrials.gov) - Jun 4, 2014
P3, N=360, Recruiting, Sponsor: Lee's Pharmaceutical Limited